The Galien Foundation has selected nominees for its award, which recognizes those therapies and technologies with the greatest potential impact on human health.
The Galien Foundation has released the list of nominees for its 2019 award, which recognizes the most innovative and important biomedical therapies and products approved within the past five years.
"We are blessed to live in a time of exciting scientific, medical, and technological advances that promise a revolution in cures, treatments, and tools for patients everywhere,"" said Dr.Sue Desmond-Hellmann, chair of the Prix Galien USA Awards Committee and CEO of the Bill & Melinda Gates Foundation. "The 2019 nominees demonstrate this incredible potential across multiple platforms and reflect the abundance of new science that underpins the Galien Foundation's mission to improve the human condition."
This year’s nominees include:
·The first FDA-approved drugs using RNA interference technology and targeted mutation gene therapy
·The first of a new line of 'tissue agnostic' cancer-fighting drugs
·A new class of female contraceptives designed for use in resource-limited settings
·Novel inhalation devices that enhance dosing accuracy against major chronic conditions such as asthma and COPD
·The first FDA-approved therapy for endometriosis pain in more than a decade
·The first in a new class of anti-epileptic drugs
·The first prescription product derived from the cannabis plant
·The first prescription digital therapeutic to address the opioid abuse crisis through interactive engagement between patient and clinician
Among the nominees for best biotech product of 2019 are:
Amgen’s Aimoviq (erenumab-acce)
Portola’s Andexxa
Regeneron and Sanofi’s Dupixent
Stemline Therapeutics’ ELZONRIS
Lilly’s Emgality
Amicus’ GALAFOLD
Genentech’s Hemlibra
Spark Therapeutics’ LUXTURNA
Ainylam’s ONPATTRO
BioMarin’s Palynziq
GlaxoSmithKline’s SHINGRIX
Janssen’s TTREMFYA
Takeda’s TAKHZYRO
Nominees for best pharmaceutical product include The Population Council’s ANNOVERA, Pfizer’s DAURISMO, Janssen’s ERLEADA, and AstraZeneca’s LUMOXITI.
Nominees for best medical product of the year include Lynch Biologics’ Augment Injectable Bone Graft, Boston Scientific’s AXIOS stent, and Abbott’s FreeStyle Libre 14-day flash glucose monitoring system.
For a full list of the nominees, please see the Foundation’s Press Release.
Winners will be announced during the Prix Galien USA Awards Ceremony on October 24, 2019 at the American Museum of Natural History in New York City.Registration to attend the 2019 Prix Galien Awards Ceremony can be accessed at http://register.prix-galien-usa.com
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.